Context Therapeutics (CNTX) Amortization of Deferred Charges (2020 - 2021)

Context Therapeutics' (CNTX) quarterly Amortization of Deferred Charges came in at -$18240.0 in Q4 2021, down 119.32% year-on-year from $94434.0 in Q4 2020, and down 1546.47% quarter-over-quarter from $1261.0 in Q3 2021.

Context Therapeutics (CNTX) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends

Context Therapeutics has disclosed Amortization of Deferred Charges across 2 years of filings, most recently posting -$18240.0 for Q4 2021.

  • Amortization of Deferred Charges for Q4 2021 came in at -$18240.0, down 119.32% year-over-year; the trailing twelve-month figure through Sep 2022 was -$18240.0 (down 111.47% YoY), and the FY2021 annual result was $46315.0, down 93.0% from the prior year.
  • Amortization of Deferred Charges came in at -$18240.0 for Q4 2021 at Context Therapeutics, down from $1261.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $94434.0 in Q4 2020 to a low of -$18240.0 in Q4 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn -
7 Psyence Biomedical 241.78 Bn 241.78 Bn -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn
9 Abivax 94.26 Bn 94.26 Bn -
10 Context Therapeutics 166.57 Mn 166.57 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2021 -18,240.00
Dec 31, 2021 -18,240.00
Sep 30, 2021 1,261.00
Sep 30, 2021 1,261.00
Jun 30, 2021 309.00
Jun 30, 2021 309.00
Mar 31, 2021 62,985.00
Mar 31, 2021 62,985.00
Dec 31, 2020 94,434.00
Dec 31, 2020 94,434.00